Genenta Science Spa Stock Today
| GNTA Stock | USD 3.92 0.10 2.62% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Genenta Science is trading at 3.92 as of the 20th of March 2025, a 2.62% increase since the beginning of the trading day. The stock's open price was 3.82. Genenta Science has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of December 2021 | Category Healthcare | Classification Health Care |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company was incorporated in 2014 and is headquartered in Milan, Italy. The company has 18.29 M outstanding shares of which 2.53 K shares are currently shorted by private and institutional investors with about 0.26 trading days to cover. More on Genenta Science SpA
Moving together with Genenta Stock
Moving against Genenta Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Genenta Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman CoFounder | Pierluigi Paracchi |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation | |
Genenta Science SpA (GNTA) is traded on NASDAQ Exchange in USA. It is located in Via Olgettina No. 58, Milan, MI, Italy, 20132 and employs 14 people. Genenta Science is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 71.7 M. Genenta Science SpA conducts business under Biotechnology sector and is part of Health Care industry. The entity has 18.29 M outstanding shares of which 2.53 K shares are currently shorted by private and institutional investors with about 0.26 trading days to cover.
Genenta Science SpA currently holds about 37.24 M in cash with (11.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04.
Check Genenta Science Probability Of Bankruptcy
Ownership AllocationGenenta Science SpA has a total of 18.29 Million outstanding shares. Genenta Science secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genenta Ownership Details
Genenta Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alti Global Inc | 2024-12-31 | 200.3 K | |
| Allianz Se | 2024-12-31 | 103.2 K | |
| Algebris Investment Management (uk) Llp | 2024-12-31 | 45 K | |
| Citadel Advisors Llc | 2024-12-31 | 11.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 0.0 | |
| Ubs Group Ag | 2024-12-31 | 0.0 |
Genenta Science Historical Income Statement
Genenta Stock Against Markets
Genenta Science Corporate Management
| Carlo MD | Chief Development | Profile | |
| Richard Slansky | Chief Officer | Profile | |
| Tim Obara | Head Devel | Profile | |
| Luigi MD | CoFounder Board | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genenta Science SpA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genenta Science. If investors know Genenta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genenta Science listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Genenta Science SpA is measured differently than its book value, which is the value of Genenta that is recorded on the company's balance sheet. Investors also form their own opinion of Genenta Science's value that differs from its market value or its book value, called intrinsic value, which is Genenta Science's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genenta Science's market value can be influenced by many factors that don't directly affect Genenta Science's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genenta Science's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genenta Science is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genenta Science's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.